EVOLUTION
Evolution
when disruptive innovations multiply
Scientific innovations are giving rise to tremendous hopes for treatment and prevention.
At the same time, the cost of research and development is drastically increasing at the same rate as complexity. Faced with the need to contain the financial impact, Life Sciences companies are looking for solutions: rationalization through specialization, partnerships, structural change, and many other initiatives are all reasons to team up with Humanim to successfully carry out your evolutions.
SCIENCE MOVES FORWARD
FOR THE BENEFIT OF ALL
Cell therapy, RNA technology, nanoparticulate lipid formulation, autologous manufacturing, drug-digital combination and other recent innovations are leading to new therapeutic paths. This requires a new approach to pharmaceutical development, industrialization and production processes. Humanim is committed to defining and supporting the necessary evolution of companies to meet these new challenges.
The path of a drug, from discovery to production, is extremely complex. The multiplication of research sites offers hope to many patients and practitioners. Humanim is committed to making this a successful challenge for companies.
Our methodology for supporting organizations
in their transformation
DIVERSIFICATION OR SPECIALIZATION, A DELICATE BALANCE
Over the past decade, the number of new research areas and therapeutic applications has increased significantly. This has led Life Sciences industries to strengthen their efforts in a targeted manner.
The number of mergers, reorganizations and creations of structures has multiplied to meet the need to remain at the forefront of a certain number of therapeutic areas. All Life Sciences players are concerned and must reconcile diversification and specialization. Humanim's expertise is available to advise them on the most appropriate choice.
Let's talk strategy
FINANCIAL PRESSURE AND ACCESSIBILITY OF INNOVATION
Health comes at a price. The average cost of drug development has risen further over the decade. Public and private payers are struggling to contain inflation without penalizing patients. In this context of uncertain economic equilibrium, the innovation ecosystem is constantly being renewed. This permanent revolution is not without impact on the organization of companies and the feelings of their employees.
The involvement and efficiency of teams can be affected. The societal stakes involved in major advances (autoimmune diseases, cellular and gene therapies, etc.) are not always sufficient to better support the constraints of speed, agility and productivity. There is no single solution. Humanim's approach and support is specific to each situation, whether you are looking to improve performance, develop new collaborations, or create new companies.
MEETING YOUR CHALLENGES
JOIN THE INNOVATION MOVEMENT WITH THE MAJOR PLAYERS IN THE SECTOR
The ability to establish sustainable and coherent strategic partnerships is becoming an essential requirement for any life sciences company. Lay the right foundations for your innovation or scientific breakthrough by relying on the network and experience of Humanim experts.
Humanim's core business is the fine-tuning of the drug life cycle. A fervent promoter of the "Quality by Design" philosophy, Humanim, through its cross-functional team of experts, brings you know-how acquired and proven in the life sciences sector. Active ingredients derived from biotechnologies, gene therapies, messenger RNA, sterile products, etc. are all covered by Humanim's technical, operational, and strategic missions.
“
Continuing to improve public health through innovation
”
Learn more about our partnership expertise
